联合王国NHS肥胖症药物的获取限制了高风险群体,有可能加深健康不平等。 UK's NHS obesity drug access limits high-risk groups, risking deeper health inequalities.

英国的肥胖症治疗有双重风险,因为由于诊断不足和地区差异,对像Mounjaro这样的药物的严格国民保健制度资格排除了许多高风险个人,包括妇女、少数群体和低收入病人。 UK obesity treatment risks a two-tier system as strict NHS eligibility for drugs like Mounjaro excludes many high-risk individuals, including women, minorities, and low-income patients, due to under-diagnosis and regional disparities. 专家警告说,通过国民保健制度获得的有限服务,虽然私人使用增加,但可能加深健康不平等。 Experts warn that limited access through the NHS, while private use grows, could deepen health inequalities. 他们敦促改变政策,优先考虑临床需求,扩大支助服务,整合更广泛的公共卫生措施,以确保公平护理。 They urge policy changes to prioritize clinical need, expand support services, and integrate broader public health measures to ensure equitable care.